Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?

Objectives The role of concomitant chemoradiotherapy or radiotherapy (RT) after induction chemotherapy (IC) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma is debatable. This systematic review aimed to explore this. Methods We searched PubMed, MEDLINE, EMBASE, and Cochrane database. Studies were selected reporting outcomes on resection rate, R0 resection, pathological response, radiological response, progression-free survival, overall survival, local control, morbidity, and mortality. Results The search resulted in 6635 articles. After 2 rounds of screening, 34 publications were selected. We found 3 randomized controlled studies and 1 prospective cohort study, and the rest were retrospective studies. There is consistent evidence that addition of concomitant chemoradiotherapy or RT after IC improves pathological response and local control. There are conflicting results in terms of other outcomes. Conclusions Concomitant chemoradiotherapy or RT after IC improves local control and pathological response in borderline resectable and locally advanced pancreatic ductal adenocarcinoma. The role of modern RT in improving other outcome requires further research.

[1]  M. Lotze,et al.  Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case–Control Matched Analysis , 2020, Annals of Surgical Oncology.

[2]  J. Winter,et al.  Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. , 2020, American journal of surgery.

[3]  B. Erickson,et al.  Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. , 2020, Surgery.

[4]  A. Livingstone,et al.  The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients , 2020, Clinical Medicine Insights. Oncology.

[5]  S. Maithel,et al.  Optimal timing and treatment strategy for pancreatic cancer , 2020, Journal of surgical oncology.

[6]  B. Erickson,et al.  Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer , 2020, Frontiers in Oncology.

[7]  Jeffrey E. Lee,et al.  The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer , 2020, Annals of Surgical Oncology.

[8]  A. Ejaz,et al.  Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. , 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[9]  M. Kendrick,et al.  Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. , 2020, Surgery.

[10]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[11]  G. Molina,et al.  Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer , 2019, Annals of Surgical Oncology.

[12]  M. Büchler,et al.  Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. , 2019, JAMA surgery.

[13]  N. Takahashi,et al.  Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis , 2019, Journal of surgical oncology.

[14]  J. Cameron,et al.  Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  V. Verma,et al.  Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. , 2019, Journal of gastrointestinal oncology.

[16]  S. Maithel,et al.  Induction Therapy in Localized Pancreatic Cancer. , 2019, Pancreas.

[17]  J. Cameron,et al.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.

[18]  T. Fitzgerald,et al.  Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer , 2019, Annals of Surgical Oncology.

[19]  Jeffrey E. Lee,et al.  Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. , 2019, Annals of surgery.

[20]  B. Erickson,et al.  Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. , 2019, Surgery.

[21]  R. Bianco,et al.  Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review , 2019, Cancers.

[22]  E. B. Butler,et al.  Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma , 2019, Acta oncologica.

[23]  A. Biankin,et al.  PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. , 2019, Journal of Clinical Oncology.

[24]  T. Ohtsuka,et al.  Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery , 2019, Annals of Surgical Oncology.

[25]  M. Büchler,et al.  Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer , 2019, Annals of surgery.

[26]  R. Shridhar,et al.  Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. , 2019, Journal of gastrointestinal oncology.

[27]  A. Biankin,et al.  Precision-Panc Master Protocol: Personalizing treatment for pancreatic cancer ISRCTN14879538—Part of Precision-Panc United Kingdom. , 2019, Journal of Clinical Oncology.

[28]  T. Fujii,et al.  Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery , 2019, Annals of Surgical Oncology.

[29]  J. Vaillant,et al.  How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort , 2018, Annals of Surgical Oncology.

[30]  M. Makary,et al.  Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy , 2018, Journal of Gastrointestinal Surgery.

[31]  J. Windsor,et al.  Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer , 2018, ANZ journal of surgery.

[32]  G. Tienhoven,et al.  Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer , 2018, The British journal of surgery.

[33]  Jeffrey E. Lee,et al.  Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma , 2017, JAMA surgery.

[34]  Lynette M. Smith,et al.  Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients , 2017, World Journal of Surgical Oncology.

[35]  M. Makary,et al.  Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer , 2017, Cancer medicine.

[36]  Y. Chiu,et al.  The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[37]  N. Jamieson,et al.  The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. , 2017, Journal of gastrointestinal oncology.

[38]  D. Bentrem,et al.  Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. , 2017, American journal of surgery.

[39]  Jeffrey E. Lee,et al.  Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma , 2016, Cancer.

[40]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[41]  Jeffrey E. Lee,et al.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality , 2016, Journal of Gastrointestinal Surgery.

[42]  M. Bloomston,et al.  Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas , 2015, Annals of Surgical Oncology.

[43]  T. Pawlik,et al.  The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. , 2015, Seminars in oncology.

[44]  D. Gouma,et al.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). , 2014, Surgery.

[45]  S. Corrao,et al.  Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of prospective studies , 2012 .

[46]  L. Hartling,et al.  Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item Bank , 2013 .

[47]  E. Van Cutsem,et al.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Jeffrey W. Clark,et al.  Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer , 2012, Cancer.

[49]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[50]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  G. Eslick,et al.  A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[52]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[53]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[55]  P. Engstrom,et al.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Macfarlane,et al.  Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. , 1981, Journal of the Canadian Association of Radiologists.

[57]  C. Ohe,et al.  Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy , 2016, Surgery Today.

[58]  F. Carbonnel,et al.  FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort , 2014, Annals of Surgical Oncology.

[59]  G. La Torre,et al.  A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer , 2009, Annals of Surgical Oncology.

[60]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.